A practical distribution pattern of α-SMA-positive carcinoma associated fibroblasts indicates poor prognosis of patients with pancreatic ductal adenocarcinoma by Bo Li, Meilong Shi, Yang Wang, Penghao Li, Xiaoyi Yin, Guoxiao Zhang, Xiaochao Kang, Huan Wang, Suizhi Gao, Kailian Zheng, Xiaohan Shi, Xiongfei Xu, Yukun Zhou, Hui Jiang, Wei Jing, Shiwei Guo, Gang Jin

“…RNA sequencing analysis revealed that the differentially expressed genes (DEGs) in Type I CAFs are closely associated with those in corresponding tumor tissues, highlighting the enhanced biological significance of immune-related and oncogenic invasive pathways.Conclusions Our findings that two types of α-SMA-positive CAFs with different spatial patterns present heterogeneously across tissues of PDACs and correlated with patients’ outcomes. …”
Get full text

The miR-23a/27a/24 − 2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer by Hao Luo, Bin Hu, Xiang-Rong Gu, Jing Chen, Xiao-Qing Fan, Wei Zhang, Ren-Tao Wang, Xian-Dong He, Wei Guo, Nan Dai, Dan Jian, Qing Li, Cheng-Xiong Xu, Hua Jin

“…The overexpression of all miRNAs in the miR-23a/27a/24 − 2 cluster upregulated PD-L1 expression by targeting Cbl proto-oncogene B (CBLB) and downregulated MHC-I expression by increasing the level of eukaryotic initiation factor 3B (eIF3B) via the targeting of microphthalmia-associated transcription factor (MITF). …”
Get full text

NOX4 modulates breast cancer progression through cancer cell metabolic reprogramming and CD8+ T cell antitumor activity by Yingying Xiong, Yiming Weng, Shan Zhu, Jian Qin, Jia Feng, Xiaopeng Jing, Chao Luo, Wei Gong, Rui Sun, Min Peng

“…Although NADPH oxidase 4 (NOX4) has been implicated in various oncogenic processes, its exact function in breast cancer progression, metabolic reprogramming, and immune modulation remains unclear.MethodsWe used murine 4T1 and EO771 breast cancer models to generate NOX4 knockout (KO) cell lines via CRISPR/Cas9. …”
Get full text

NCAPD3 promotes diffuse large B-cell lymphoma progression through modulating SIRT1 expression in an H3K9 monomethylation-dependent manner by Tiange Lu, Juan Yang, Yiqing Cai, Mengfei Ding, Zhuoya Yu, Xiaosheng Fang, Xiangxiang Zhou, Xin Wang

“…Function reversion assay verified the oncogenic role of NCAPD3 in DLBCL was partially mediated by SIRT1. …”
Get full text

Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression by Weijuan Zhang, Jiejie Xu, Hailong Liu, Yu Zhu, Zewei Wang, Han Zeng, Zhaopei Liu, Yuan Chang, Le Xu, Kaifeng Jin, Jingtong Xu, Xiaohe Su, Yawei Ding, Lingkai Zhang, Jiaxing Sun, Yuzhen Wu

“…Background The E3 ubiquitin ligase murine double minute 2 (MDM2) binds the p53 transcriptional activation domain and acts as a potent inhibitor of TP53 pathway, one of the three most crucial oncogenic pathways in urothelial carcinoma (UC). However, the clinical significance and impact on tumor immune contexture of MDM2 amplification in UC remain unclear.Methods This study analyzed 240 patients with UC with matched clinical annotations from two local cohorts (ZSHS cohort and FUSCC cohort). …”
Get full text

Divergent paths of mammary gland involution: unveiling the cellular dynamics in abruptly and gradually involuted mouse models by Sarmila Majumder, Sanjay Mishra, Neelam Shinde, Maria C. Cuitino, Morgan Bauer, Dinesh Ahirwar, Mustafa M. Basree, Vijaya Bharti, Kate Ormiston, Resham Mawalkar, Sara Alsammerai, Gautam Sarathy, Anna E. Vilgelm, Xiaoli Zhang, Ramesh K. Ganju, Bhuvaneswari Ramaswamy

“…At the peak of cell death, AI glands harbored more immunosuppressive myeloid-derived suppressor cells (MDSCs) and CD206 + M2-like macrophages, known to promote oncogenic events, compared to GI glands. AI glands exhibit an enrichment of CCL9-producing MDSCs and CD206 + M2-like macrophages that promote expansion of ELF5 + /ERα- luminal cells, both in vitro and in vivo. …”
Get full text

TC2N maintains stem cell-like characteristics to accelerate lung carcinogenesis by blockade of dual specificity protein phosphatase 3 by Jing Gu, Yang-fan Lv, Ji-ying Xia, Fu-hai Bai, Ji Gong, Guang-qiang Pan, Bo Liu, Lu Huang, Qiao-nan Guo, Xiang-lin Hao

“…In previous studies, we have uncovered the oncogenic role and mechanisms of TC2N in lung cancer: TC2N achieves this by inhibiting the p53 signaling pathway and activating the NF-kappaB signaling pathway. …”
Get full text

Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy by Coraline Radermecker, Pascale Hubert, Patrick Roncarati, Stephanie Demoulin, Charlotte Pilard, Marie Ancion, Celia Reynders, Thomas Lerho, Diane Bruyere, Alizee Lebeau, Margot Meunier, Marie-Julie Nokin, Elodie Hendrick, Olivier Peulen, Philippe Delvenne, Michael Herfs

“…Regarding its role in cancer development/progression, paradoxical results exist in the literature and it is still unclear whether HMGB1 mainly acts as an oncogene or a tumor suppressor.Methods HMGB1 expression was first assessed in tissue specimens (n=359) of invasive breast, lung and cervical cancer and the two distinct staining patterns detected (nuclear vs cytoplasmic) were correlated to the secretion profile of malignant cells, patient outcomes and the presence of infiltrating immune cells within tumor microenvironment. …”
Get full text

Importance of EQA/PT for the detection of genetic variants in comprehensive cancer genome testing by Kazuyuki Matsushita, Takayuki Ishige, Kousuke Watanabe, Toshiaki Akahane, Akihide Tanimoto, Michiko Yoshimoto, Munekazu Yamakuchi, Teruto Hashiguchi, Yoshinaga Okugawa, Makoto Ikejiri, Toshikazu Yamaguchi, Tadashi Yamasaki, Mayu Takeda, Masaaki Hibi, Naoki Akiyama, Kaho Shimizu, Naonori Hashimoto, Hiroko Sato, Yoshinori Tanaka, Fumie Amari, the EQA working group of Japan Association for Clinical Laboratory Science(JACLS)

“…First, EQA with extracted DNA from cell lines showed a detection rate of 100% (9 out of 9) in KRAS (c.38G > A; p.G13D), PIK3CA (p.H1047R), and B-Raf proto-oncogene, serine/threonine kinase (BRAF) (c.1799 T > A; p.V600E) in cases of > 10% variant allele frequency (VAF). …”
Get full text

miR-9-5p/HMMR regulates the tumorigenesis and progression of clear cell renal cell carcinoma through EMT and JAK1/STAT1 signaling pathway by Xinyang Niu, Dingheng Lu, Weitao Zhan, Jiazhu Sun, Yuxiao Li, Yuchen Shi, Kai Yu, Suyuelin Huang, Xueyou Ma, Xiaoyan Liu, Ben Liu

“…Knocking down HMMR inhibited the proliferative and migratory abilities of ccRCC cells, while its overexpression amplified these oncogenic properties. In nude mice model, reduced HMMR expression inhibited ccRCC tumor proliferation in vivo. …”
Get full text

Clinical and molecular analysis of JCPyV and BKPyV infection and associated risk of urothelial carcinoma development in the upper tract by Chun-Nun Chao, Chi-Feng Hung, Wei‑Hong Lai, Chun-Liang Tung, Wan-Yun Yeh, Kai-Wu Yang, Meilin Wang, Ya-Yan Lai, Pei-Lain Chen, Cheng-Huang Shen

“…Abstract Background Human polyomaviruses (HPyVs), JC polyomavirus (JCPyV) and BK polyomavirus (BKPyV), have been found in upper tract urothelial carcinoma UTUC; however, the association of the viral oncogenic factors and clinical characteristics of UTUC remains unclear. …”
Get full text

Oncometabolite D-2HG drives tumor metastasis and protumoral macrophage polarization by targeting FTO/m6A/ANGPTL4/integrin axis in triple-negative breast cancer by Siyue Zhang, Ning Zhang, Tong Wan, Yinqiao He, Jie Hao, Yiwei Liu, Yidong Liu, Bing Chen, Wenjing Zhao, Lijuan Wang, Dan Luo, Chao Gao, Qifeng Yang

“…Results We found that D-2HG accumulated in triple-negative breast cancer (TNBC), exerting oncogenic effects both in vitro and in vivo by promoting TNBC cell growth and metastasis. …”
Get full text

HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAFV600E-mutant microsatellite stable colorectal cancer by Xin Li, Peng Yang, Jin Gu, Nan Chen, Dengbo Ji, Jinhong Xia, Jinying Jia, Zhuang Sun, Mengyuan Shi, Hanyang Wang, Zhaoya Gao

“…Background B-Raf proto-oncogene, serine/threonine kinase (BRAF)V600E-mutant microsatellite stable (MSS) colorectal cancer (CRC) constitutes a distinct CRC subgroup, traditionally perceived as minimally responsive to standard therapies. …”
Get full text

CYFIP2: potential pancreatic cancer biomarker and immunotherapeutic target by Cong Xiao, Xiaojuan Zhang, Bobo Hou, Ping Wan, Zhenjun Cao, Xuefeng Rao

“…In this work, we first explain the great potential of CYFIP2 malignant progression from a broader perspective (pan-cancer) and confirm its oncogenic value in pancreatic cancer. Methods The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx) database, CELL and GEO databases were utilized to explore the distribution of the CYFIP2 gene in human cancers. …”
Get full text

A KSHV RNA-binding protein promotes FOS to inhibit nuclease AEN and transactivate RGS2 for AKT phosphorylation by Vladimir Majerciak, Beatriz Alvarado-Hernandez, Yanping Ma, Shivalee Duduskar, Alexei Lobanov, Maggie Cam, Zhi-Ming Zheng

“…Altogether, we have discovered that KSHV ORF57 specifically binds and stabilizes FOS RNA to increase FOS expression, thereby disturbing host gene expression and inducing pathogenesis during KSHV lytic infection.IMPORTANCEWe discovered that FOS, a heterodimer component of oncogenic transcription factor AP-1, is highly elevated in KSHV-infected cells by expression of a viral lytic RNA-binding protein, ORF57, which binds a 13-nt RNA motif near the FOS RNA 5′ end to prolong FOS RNA half-life. …”
Get full text

Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer—results from the FIRE‐4.5 study by Susanne Klein‐Scory, Alexander Baraniskin, Wolff Schmiegel, Thomas Mika, Roland Schroers, Swantje Held, Kathrin Heinrich, David Tougeron, Dominik P. Modest, Ingo Schwaner, Jan Eucker, Rudolf Pihusch, Martina Stauch, Florian Kaiser, Christoph Kahl, Meinolf Karthaus, Christian Müller, Christof Burkart, Sebastian Stintzing, Volker Heinemann

“…The randomized FIRE‐4.5 (AIO KRK0116) trial compared first‐line therapy with FOLFOXIRI (folinic acid, fluorouracil, oxaliplatin, and irinotecan) plus either cetuximab or bevacizumab in B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) V600E‐mutant metastatic colorectal cancer (mCRC) patients. …”
Get full text

EGFR inhibition augments the therapeutic efficacy of the NAT10 inhibitor Remodelin in Colorectal cancer by Yongbin Zheng, Dan Song, Ming Guo, Chenhong Wang, Mingzhen Ma, Gongcai Tao, Licui Liu, Xiaobo He, Fengyu Cao, Dan Luo, Qingchuan Zhao, Zhongyuan Xia, Yanxin An

“…Results We found that NAT10 is highly expressed in CRC samples and plays a pro-oncogenic role. NAT10 knockdown led to PI3K-AKT pathway inactivation, thereby inhibiting CRC progression. …”
Get full text

The protein composition of human adenovirus replication compartments by Paloma Hidalgo, Amada Torres, Pierre M. Jean Beltran, Gamaliel López-Leal, Luca D. Bertzbach, Thomas Dobner, S. J. Flint, Ileana M. Cristea, Ramón A. González

“…In addition, we validated newly identified proteins associated with RCs, including the high mobility group box 1 (HMGB1), the SET nuclear proto-oncogene, the structure-specific recognition protein 1 (SSRP1), the CCCTC-binding protein (CTCF), and sirtuin 6 (SIRT6). …”
Get full text

Extended HPV genotyping by the BD Onclarity assay: concordance with screening HPV-DNA assays, triage biomarkers, and histopathology in women from the NTCC2 study by Laura De Marco, Simonetta Bisanzi, Guglielmo Ronco, Pamela Mancuso, Francesca Carozzi, Elena Allia, Raffaella Rizzolo, Daniela Gustinucci, Helena Frayle, Jessica Viti, Anna Iossa, Elena Cesarini, Simonetta Bulletti, Basilio Passamonti, Silvia Gori, Laura Toniolo, Francesco Venturelli, Annarosa Del Mistro, Paolo Giorgi Rossi, Maria Benevolo

“…ABSTRACT The use of clinically validated human papillomavirus (HPV) assays is recommended in cervical cancer screening, and extended genotyping is getting attention as a triage biomarker because of the different oncogenic risk of the high-risk HPV genotypes. We compared the results of the Becton & Dickinson (BD) Onclarity HPV assay, on the residual baseline cervico-vaginal specimens of the NTCC2 trial, to those of the screening HPV-DNA assay (Cobas 4800 or HC2) and to cytology, p16/ki67 and E6/E7 mRNA triage results. …”
Get full text